Non-alcoholic Fatty Liver Disease
Conditions
Keywords
gut microbiota, Non Alcoholic Steato Hepatitis, Steatohepatitis, Escherichia coli, colibactin
Brief summary
In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis. The purpose of this study is to determine if the pathogenic Escherichia Coli to the B2 group and producing the genotoxin colibactin is a factor for developing NASH.
Detailed description
Gut microbiota composition is now linked to the onset of obesity, metabolic disorders, and Non Alcoholic Fatty Liver Disease . While simple steatosis has benign prognosis, steatohepatitis (NASH) leads to cirrhosis and hepatocarcinoma and increases cardiovascular and cancer- related mortality. Some Escherichia coli (E. coli) belonging to the B2 phylogenetic group are involved in many diseases. Those producing the genotoxin colibactin are in addition known to induce a chronic alteration of intestinal permeability, one of the major factors leading to NASH.
Interventions
BIOLOGICALliver biopsy
A small needle is inserted into the liver to collect a tissue sample
BIOLOGICALcollection of stools
collection of stools
BIOLOGICALblood sample
collection of blood sample
Sponsors
University Hospital, Toulouse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* NAFLD * indication of liver biopsy
Exclusion criteria
* presence of any other cause of liver or steatosis * alcohol consumption exceeding 30 g / day for a men and 20 g / day for a woman * a history of decompensated cirrhosis * treatment with prebiotics, probiotics or antibiotics in the month prior to inclusion * chronic gastrointestinal disease or history of gastrointestinal surgery * pregnancy or breastfeeding * patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| composition of the gut microbiota between two groups, and prevalence of the Escherichia Coli belonging to the B2 group and producing the genotoxin colibactin. | 1 day | compare the composition of the gut microbiota between patients with simple steatosis with steatohepatitis, and determinate the prevalence of the Escherichia Coli belonging to the B2 group and producing the genotoxin colibactin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| differences between the two groups | 1 day | highlight other differences between the two cohort |
| determine wether bacteria, in particular escherichia Coli can translocate and reach steatohepatitis patients liver | 1 day | determine if bacteria, in particular escherichia Coli can translocate and reach steatohepatitis patients liver |
| Exploration of a biomarker of fibrosis from blood microbiota in NAFLD patients | 1 day | Determination of bacterial translocation assay PCR 16S bacterial gene in blood and sequence and analyse the microbiota. |
Countries
France
Outcome results
None listed